Clinical Dilemmas in Diabetes. Группа авторов

3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes – 2020. Diabetes Care. 2020; 43(Suppl 1):S32–S36.

      104 104. Hu W et al. Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle‐aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross‐sectional study. BMC Endocr Disord. 2015; 15:47.

      105 105. Kannan MA et al. Prevalence of neuropathy in patients with impaired glucose tolerance using various electrophysiological tests. Neurol India. 2014; 62(6):656–661.

      106 106. Wu JS et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007; 92(10):3885–3889.

      107 107. Holman RR et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2017; 5(11):877–886.

2 Early Diagnosis of Type 1 Diabetes – Useful or a Pyrrhic Victory?

       Paolo Pozzilli and Silvia Pieralice

      Department of Endocrinology & Diabetes, Campus Bio‐Medico University of Rome, Rome, Italy

      LEARNING POINTS

       Making an early diagnosis of type 1 diabetes can permit intervention with agents that could modify the course of disease.

       Numerous clinical trials have attempted to change the course of disease or prevent its onset. Of these, early immune intervention holds the most promise.

Introduction

      Type 1 diabetes (T1D) is one of the most widespread chronic disease occurring in children and young adults. In 2001, people with diabetes (all types included) were 177 million worldwide, in 2010 285 million, in 2019 approximately 463 million and it is predicted that some 700 million people worldwide will live with diabetes in 2045 [1].

      As the prevalence of diabetes continues to rise worldwide, disease‐related morbidity and mortality are emerging as major healthcare problems. Epidemiologic data show that diabetes‐related long‐term complications begin early in the natural history of the disease . These findings indicate that early identification and management of individuals at increased risk of T1D has the potential to reduce both the clinical onset of the disease and its related complications.

      The global incidence of T1D in children and adolescents is rising with an estimated overall annual increase of approximately 3%. These recent epidemiologic trends in T1D have been shown in countries having both high and low prevalence figures, with an indication of a steeper increase in some of the low‐prevalence countries. T1D accounts for about 10% of all cases of diabetes, occurs most commonly in people of European descent and affects 2 million people in Europe and North America [1]. The lowest incidence has been found in Asia and Oceania, the highest in Europe.

      As far as its pathogenesis is concerned, T1D results from the autoimmune destruction of pancreatic insulin‐secreting β‐cells. Genetic, metabolic, and environmental factors act together to precipitate the onset of the disease. The excess mortality associated with diabetes‐related complications and the increasing prevalence of the disease among the youth, emphasize the importance of novel therapeutic strategies to prevent or slow down the autoimmune process.

Pathogenesis of T1D: An Update in View of Defining Preventive Tools

There are three main categories of factors involved in the pathogenesis of T1D. These are genetic, immunological, and environmental factors (Figure 2.1).

Like other organ‐specific autoimmune diseases, T1D shows specific human leukocyte antigen (HLA) associations. The HLA complex on chromosome 6 comprises the first gene shown to be associated with the disease and it is considered to contribute to almost half of the familial basis of T1D. Two combinations of HLA haplotypes are of particular importance. They are DR4‐DQ8 and DR3‐DQ2, which are present in 90% of children with T1D [5]. A third haplotype, DR15‐DQ6, is found in less than 1% of children with T1D, compared to more than 20% of the general population, and it is considered to be protective. The genotype combining the two susceptibility haplotypes (DR4‐DQ8/DR3‐DQ2) contributes to the greatest risk of the disease and it appears frequently in children with an earlier onset. First‐degree relatives of these children are themselves at greater risk of T1D compared to those of children in whom the disease develops later.

FIG 2.1 Pathogenesis and natural history of Type 1 diabetes. Atkinson MA and Eisenbarth GS Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358(9277):221–229.

      Candidate gene studies also identified the insulin gene on chromosome 11 as another important genetic susceptibility factor, contributing 10% of the genetic susceptibility to T1D [6]. Similarly, an allele of the gene acting as a negative regulator of T‐cell activation, cytotoxic T lymphocyte antigen 4 (CTLA‐4), found on chromosome 2q33, is considered to be another susceptibility gene for T1D [7]. A variant of PTPN22, the gene encoding Lymphoid Phosphatase (LYP), which is a suppressor of T‐cell activation, has been deemed as another susceptibility gene [8]. Similarly, variation in IL2RA which encodes the α‐chain of the IL‐2 receptor is also associated with T1D [9]. The observation that these susceptibility genes for T1D all play important roles in antigen presentation to T‐cells, emphasizes the potential importance of current therapeutic strategies targeting this interaction [10].

      Genetic studies have highlighted the importance of large, well‐characterized populations in the identification of susceptibility genes for T1D. Recruitment of increasingly large populations of patients with T1D and their families is required to provide statistically powerful cohorts in which to identify other disease‐associated genes. Some genes have a relatively minor individual impact on susceptibility to disease but could nevertheless provide more clues to future preventive therapies.

The presence of autoantibodies to β‐cells is the hallmark of T1D (Figure 2.1). Abnormal activation of the T‐cell‐mediated immune system in susceptible individuals leads to an inflammatory response within the islets as well as to a humoral response with production of antibodies to β‐cell antigens. Islet‐cell antibodies (ICA) were the first ones described, followed by more specific autoantibodies to insulin (IAA), glutamic acid decarboxylase (GAD), the protein tyrosine phosphatase (IA‐2), and most recently Zinc Transporter 8 (ZnT8A), all of which can be easily detected by sensitive radioimmunoassay to identify subjects at risk of developing T1D [11]. These autoantibodies are common in both childhood and adult onset T1D, with many subjects being positive for multiple autoantibodies. The type of immune response is age‐dependent, but seroconversion to multiple autoantibody positivity usually occurs tightly clustered in time and is associated with genetic risk.

      The presence of one or more type of antibodies can precede the clinical onset of T1D by years or even decades. These autoantibodies are usually persistent, although a small group of individuals may revert to being seronegative without progressing to clinical diabetes. The presence and persistence of positivity to multiple antibodies increases the likelihood of progression to clinical disease.

      On that note, recent evidence shows that antibodies specific to oxidative post‐translationally modified insulin (oxPTM‐INS) are present